180 related articles for article (PubMed ID: 36439452)
1. A phase I/II escalation trial design T-RAD: Treatment of metastatic lung cancer with mRNA-engineered T cells expressing a T cell receptor targeting human telomerase reverse transcriptase (hTERT).
Maggadóttir SM; Kvalheim G; Wernhoff P; Sæbøe-Larssen S; Revheim ME; Josefsen D; Wälchli S; Helland Å; Inderberg EM
Front Oncol; 2022; 12():1031232. PubMed ID: 36439452
[TBL] [Abstract][Full Text] [Related]
2. Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy.
Dillard P; Köksal H; Maggadottir SM; Winge-Main A; Pollmann S; Menard M; Myhre MR; Mælandsmo GM; Flørenes VA; Gaudernack G; Kvalheim G; Wälchli S; Inderberg EM
Mol Ther; 2021 Mar; 29(3):1199-1213. PubMed ID: 33212301
[TBL] [Abstract][Full Text] [Related]
3. Development of a novel redirected T-cell-based adoptive immunotherapy targeting human telomerase reverse transcriptase for adult T-cell leukemia.
Miyazaki Y; Fujiwara H; Asai H; Ochi F; Ochi T; Azuma T; Ishida T; Okamoto S; Mineno J; Kuzushima K; Shiku H; Yasukawa M
Blood; 2013 Jun; 121(24):4894-901. PubMed ID: 23641014
[TBL] [Abstract][Full Text] [Related]
4. A phase 1 trial of human telomerase reverse transcriptase (hTERT) vaccination combined with therapeutic strategies to control immune-suppressor mechanisms.
Zareian N; Eremin O; Pandha H; Baird R; Kwatra V; Funingana G; Verma C; Choy D; Hargreaves S; Moghimi P; Shepherd A; Lobo DN; Eremin J; Farzaneh F; Kordasti S; Spicer J
Exp Biol Med (Maywood); 2024; 249():10021. PubMed ID: 38463391
[TBL] [Abstract][Full Text] [Related]
5. Phase 1 study of safety, tolerability and immunogenicity of the human telomerase (hTERT)-encoded DNA plasmids INO-1400 and INO-1401 with or without IL-12 DNA plasmid INO-9012 in adult patients with solid tumors.
Vonderheide RH; Kraynyak KA; Shields AF; McRee AJ; Johnson JM; Sun W; Chintakuntlawar AV; Pawlicki J; Sylvester AJ; McMullan T; Samuels R; Kim JJ; Weiner D; Boyer JD; Morrow MP; Humeau L; Skolnik JM
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34230114
[TBL] [Abstract][Full Text] [Related]
6. Immune responses and long-term disease recurrence status after telomerase-based dendritic cell immunotherapy in patients with acute myeloid leukemia.
Khoury HJ; Collins RH; Blum W; Stiff PS; Elias L; Lebkowski JS; Reddy A; Nishimoto KP; Sen D; Wirth ED; Case CC; DiPersio JF
Cancer; 2017 Aug; 123(16):3061-3072. PubMed ID: 28411378
[TBL] [Abstract][Full Text] [Related]
7. Phase 1 trial of 4-1BB-based adoptive T-cell therapy targeting human telomerase reverse transcriptase in patients with advanced refractory solid tumors.
Choi W; Lee Y; Choi BK; Park BM; Kim YH; Yun T; Lee WJ; Yoo H; Baek JY; Woo SM; Lim MC; Kwon BS
Cytotherapy; 2023 Nov; 25(11):1236-1241. PubMed ID: 37632518
[TBL] [Abstract][Full Text] [Related]
8. Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase.
Parkhurst MR; Riley JP; Igarashi T; Li Y; Robbins PF; Rosenberg SA
Clin Cancer Res; 2004 Jul; 10(14):4688-98. PubMed ID: 15269141
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer.
Brunsvig PF; Guren TK; Nyakas M; Steinfeldt-Reisse CH; Rasch W; Kyte JA; Juul HV; Aamdal S; Gaudernack G; Inderberg EM
Front Immunol; 2020; 11():572172. PubMed ID: 33324397
[TBL] [Abstract][Full Text] [Related]
10. Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes.
Vonderheide RH; Domchek SM; Schultze JL; George DJ; Hoar KM; Chen DY; Stephans KF; Masutomi K; Loda M; Xia Z; Anderson KS; Hahn WC; Nadler LM
Clin Cancer Res; 2004 Feb; 10(3):828-39. PubMed ID: 14871958
[TBL] [Abstract][Full Text] [Related]
11. Increased human telomerase reverse transcriptase (hTERT) mRNA expression but not telomerase activity is related to survival in curatively resected non-small cell lung cancer.
Metzger R; Vallbohmer D; Müller-Tidow C; Higashi H; Bollschweiler E; Warnecke-Eberz U; Brabender J; Baldus SE; Xi H; Berdel WE; Serve H; Hoelscher AH; Schneider PM
Anticancer Res; 2009 Apr; 29(4):1157-62. PubMed ID: 19414359
[TBL] [Abstract][Full Text] [Related]
12. The HLA A*0201-restricted hTERT(540-548) peptide is not detected on tumor cells by a CTL clone or a high-affinity T-cell receptor.
Purbhoo MA; Li Y; Sutton DH; Brewer JE; Gostick E; Bossi G; Laugel B; Moysey R; Baston E; Liddy N; Cameron B; Bennett AD; Ashfield R; Milicic A; Price DA; Classon BJ; Sewell AK; Jakobsen BK
Mol Cancer Ther; 2007 Jul; 6(7):2081-91. PubMed ID: 17620437
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3.
Lu YC; Parker LL; Lu T; Zheng Z; Toomey MA; White DE; Yao X; Li YF; Robbins PF; Feldman SA; van der Bruggen P; Klebanoff CA; Goff SL; Sherry RM; Kammula US; Yang JC; Rosenberg SA
J Clin Oncol; 2017 Oct; 35(29):3322-3329. PubMed ID: 28809608
[TBL] [Abstract][Full Text] [Related]
14. A Phase II Study Evaluating the Interest to Combine UCPVax, a Telomerase CD4 T
Rebucci-Peixoto M; Vienot A; Adotevi O; Jacquin M; Ghiringhelli F; de la Fouchardière C; You B; Maurina T; Kalbacher E; Bazan F; Meynard G; Clairet AL; Fagnoni-Legat C; Spehner L; Bouard A; Vernerey D; Meurisse A; Kim S; Borg C; Mansi L
Front Oncol; 2022; 12():957580. PubMed ID: 35928870
[TBL] [Abstract][Full Text] [Related]
15. Enhanced antitumor effect against human telomerase reverse transcriptase (hTERT) by vaccination with chemotactic-hTERT gene-modified tumor cell and the combination with anti-4-1BB monoclonal antibodies.
Lin X; Zhou C; Wang S; Wang D; Ma W; Liang X; Lin C; Wang Z; Li J; Guo S; Zhang Y; Zhang S
Int J Cancer; 2006 Oct; 119(8):1886-96. PubMed ID: 16708388
[TBL] [Abstract][Full Text] [Related]
16. Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer.
Su Z; Dannull J; Yang BK; Dahm P; Coleman D; Yancey D; Sichi S; Niedzwiecki D; Boczkowski D; Gilboa E; Vieweg J
J Immunol; 2005 Mar; 174(6):3798-807. PubMed ID: 15749921
[TBL] [Abstract][Full Text] [Related]
17. Antitumor effect of new multiple antigen peptide based on HLA-A0201-restricted CTL epitopes of human telomerase reverse transcriptase (hTERT).
Liao ZL; Tang XD; Lü MH; Wu YY; Cao YL; Fang DC; Yang SM; Guo H
Cancer Sci; 2012 Nov; 103(11):1920-8. PubMed ID: 22909416
[TBL] [Abstract][Full Text] [Related]
18. Immunogenic HLA-B*0702-restricted epitopes derived from human telomerase reverse transcriptase that elicit antitumor cytotoxic T-cell responses.
Adotévi O; Mollier K; Neuveut C; Cardinaud S; Boulanger E; Mignen B; Fridman WH; Zanetti M; Charneau P; Tartour E; Lemonnier F; Langlade-Demoyen P
Clin Cancer Res; 2006 May; 12(10):3158-67. PubMed ID: 16707616
[TBL] [Abstract][Full Text] [Related]
19. Artificial antigen-presenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells.
Dupont J; Latouche JB; Ma C; Sadelain M
Cancer Res; 2005 Jun; 65(12):5417-27. PubMed ID: 15958591
[TBL] [Abstract][Full Text] [Related]
20. Human telomerase reverse transcriptase-transduced human cytotoxic T cells suppress the growth of human melanoma in immunodeficient mice.
Verra NC; Jorritsma A; Weijer K; Ruizendaal JJ; Voordouw A; Weder P; Hooijberg E; Schumacher TN; Haanen JB; Spits H; Luiten RM
Cancer Res; 2004 Mar; 64(6):2153-61. PubMed ID: 15026357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
